Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 3:03 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 192 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acute Hospitalization Clear all
Completed Not applicable Interventional Results available

Short Stay Unit vs Hospitalization in Acute Heart Failure

NCT03302910
View directory record Official record
Conditions
Acute Heart Failure
Interventions
Short Stay Unit, Standard of Care
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 99 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
11
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Detroit, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Nov 1, 2026, 3:03 AM EST
Completed Phase 3 Interventional Results available

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

NCT03988634
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
sacubitril/valsartan, valsartan, sacubitril/valsartan matching placebo, valsartan matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
87
States / cities
Irvine, California • Long Beach, California • Los Angeles, California + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Nov 1, 2026, 3:03 AM EST
Recruiting No phase listed Observational

Combining Biomarkers and Electronic Risk Scores to Predict AKI in Hospitalized Patients

NCT05988658
View directory record Official record
Conditions
Acute Kidney Injury, Biomarkers
Interventions
ESTOP - AKI 2.0
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Nov 1, 2026, 3:03 AM EST
Completed Phase 3 Interventional Results available

Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure

NCT00894387
View directory record Official record
Conditions
Acute Decompensated Heart Failure, Congestive Heart Failure
Interventions
Aliskiren, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
37
States / cities
Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Nov 1, 2026, 3:03 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Varenicline In-Patient Study

NCT01413516
View directory record Official record
Conditions
Smoking Cessation
Interventions
Smoking cessation counseling, Placebo, Varenicline
Behavioral · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Nov 1, 2026, 3:03 AM EST
Not listed No phase listed Observational

Voice Analysis for Monitoring Patients With Heart Failure

NCT06566911
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Noah Labs
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Nov 1, 2026, 3:03 AM EST
Not listed Phase 2 Interventional

BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients

NCT04482595
View directory record Official record
Conditions
COVID-19, Long COVID, Pulmonary Fibrosis, Post-acute Respiratory Complications of COVID-19
Interventions
BIO 300 Oral Suspension, Placebo
Drug
Lead sponsor
Humanetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Aurora, Colorado • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Nov 1, 2026, 3:03 AM EST
Recruiting Not applicable Interventional

A Study Of Acute Decompensated Heart Failure

NCT07572955
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Lung Ultrasound
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Nov 1, 2026, 3:03 AM EST
Recruiting Phase 3 Interventional

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

NCT05261139
View directory record Official record
Conditions
COVID-19
Interventions
nirmatrelvir, ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Years to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
50
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Nov 1, 2026, 3:03 AM EST
Completed Not applicable Interventional

Care Anywhere With Community Paramedics Program to Reduce Hospitalization

NCT05232799
View directory record Official record
Conditions
Acute Illness
Interventions
Care Anywhere with Community Paramedics program
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Rochester, Minnesota • Barron, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Nov 1, 2026, 3:03 AM EST
Recruiting Not applicable Interventional

Massage Impact on Sleep in Pediatric Oncology

NCT06892158
View directory record Official record
Conditions
Cancer, Pediatric Cancer, Chemotherapy Effect, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Pediatric, Hematopoietic Stem Cell Transplantation (HSCT)
Interventions
Massage therapy, Standard of care
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
12 Years to 21 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Nov 1, 2026, 3:03 AM EST
Recruiting Phase 2 Interventional

Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients

NCT06513949
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Interventions
Atibuclimab, Placebo
Biological · Other
Lead sponsor
Implicit Bioscience
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Nov 1, 2026, 3:03 AM EST
Recruiting Phase 2 Interventional

Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension

NCT07511361
View directory record Official record
Conditions
Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency
Interventions
Tonlamarsen, Placebo
Drug
Lead sponsor
Kardigan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
13
States / cities
Arvada, Colorado • Homestead, Florida • Port Orange, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 1, 2026, 3:03 AM EST
Completed Not applicable Interventional

Low Risk Acute Coronary Syndrome

NCT01703156
View directory record Official record
Conditions
Low Risk Acute Coronary Syndrome
Interventions
Stress Test, No Stress Test
Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
30 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Nov 1, 2026, 3:03 AM EST
Terminated Phase 3 Interventional Results available

PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780541
View directory record Official record
Conditions
COVID-19
Interventions
PF-07304814, Placebo, Remdesivir
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
31
States / cities
Chula Vista, California • Los Angeles, California • Mather, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Nov 1, 2026, 3:03 AM EST
Terminated Not applicable Interventional

Study to Evaluate the Effectiveness of Cardiac Rehabilitation (Rehab) for Acute Decompensated Heart Failure Patients on 6 Minute Walk Test and Quality of Life

NCT02179242
View directory record Official record
Conditions
Heart Failure
Interventions
Cardiac rehab
Other
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Nov 1, 2026, 3:03 AM EST
Terminated Phase 2 Interventional Results available

Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

NCT04472494
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Abatacept, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Hialeah, Florida • Louisville, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Nov 1, 2026, 3:03 AM EST
Recruiting Phase 2 Interventional

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

NCT06703073
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions
Cohort A: vilobelimab, Cohort A: placebo, Cohort B: paridiprubart, Cohort B: placebo, Cohort C: bevacizumab, Cohort C: placebo
Drug
Lead sponsor
PPD Development, LP
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 1, 2026, 3:03 AM EST
Terminated No phase listed Observational

Home-Based Fluid Status Monitoring in Heart Failure Patients

NCT04013373
View directory record Official record
Conditions
Heart Failure
Interventions
SOZO Bioimpedance Spectroscopy Device
Device
Lead sponsor
ImpediMed Limited
Industry
Eligibility
21 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Canoga Park, California • Encinitas, California • Garden Grove, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Nov 1, 2026, 3:03 AM EST
Completed Not applicable Interventional

Assessment of ProEnkephalin to Detect Acute Kidney Injury (AKI)

NCT04019314
View directory record Official record
Conditions
Heart Failure, Volume Overload, Decompensated Heart Failure, Systolic Heart Failure
Interventions
Blood Collection, Blood Volume Analysis
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Nov 1, 2026, 3:03 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate Lung Ultrasound as a Method to Measure Changes in Extravascular Lung Water Induced by Positional Changes (LUPE)

NCT03146754
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Methodology
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Nov 1, 2026, 3:03 AM EST
Completed No phase listed Observational

International Study of Inflammation in COVID-19

NCT04818866
View directory record Official record
Conditions
Covid19, Outcome, Fatal, Respiratory Failure, Acute Kidney Injury, Inflammation
Interventions
SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase
Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
4,463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Nov 1, 2026, 3:03 AM EST
Active, not recruiting Phase 2Phase 3 Interventional

Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis

NCT04948203
View directory record Official record
Conditions
Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID
Interventions
Sirolimus
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Nov 1, 2026, 3:03 AM EST
Completed Phase 3 Interventional Results available

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

NCT00571649
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Rivaroxaban placebo, Enoxaparin placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
8,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
121
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Nov 1, 2026, 3:03 AM EST